FibroGen Gets 1 Anemia Patent Revived On Appeal
A London appellate court handed FibroGen a partial win on Tuesday, reviving one of its anemia treatment patents and saying that its rival Akebia's planned treatment connected to kidney disease would...To view the full article, register now.
Already a subscriber? Click here to view full article